Sustained release ranolazine formulations
US6503911B2 · kind B2 · utility
7Cited by
2References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Oct 19, 2001 |
| Grant date | Jan 7, 2003 |
| Priority date | — |
| Expiry date | Oct 19, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P9/10
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A sustained release ranolazine formulation contains an intimate mixture of ranolazine and a partially neutralized pH-dependent binder to form a film that is mostly insoluble in aqueous media below pH 4.5 and soluble in aqueous media above pH 4.5. The formulation is suitable for twice daily administration of ranolazine and is useful for controlling the rate of dissolution of ranolazine, and to maintain human plasma ranolazine levels at between 550 and 7500 ng base/mL.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.